Universal Beteiligungs und Servicegesellschaft mbH Takes $11.89 Million Position in Organon & Co. (NYSE:OGN)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Organon & Co. (NYSE:OGN - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 797,074 shares of the company's stock, valued at approximately $11,892,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.31% of Organon & Co. at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Barclays PLC lifted its holdings in Organon & Co. by 238.0% in the third quarter. Barclays PLC now owns 119,483 shares of the company's stock valued at $2,285,000 after buying an additional 84,136 shares during the period. Blue Trust Inc. grew its holdings in Organon & Co. by 107.6% during the 4th quarter. Blue Trust Inc. now owns 7,599 shares of the company's stock valued at $113,000 after buying an additional 3,938 shares in the last quarter. KBC Group NV increased its holdings in Organon & Co. by 66.6% during the 4th quarter. KBC Group NV now owns 12,899 shares of the company's stock worth $192,000 after acquiring an additional 5,155 shares during the period. Robeco Institutional Asset Management B.V. purchased a new stake in shares of Organon & Co. in the fourth quarter worth $2,263,000. Finally, EMC Capital Management boosted its position in shares of Organon & Co. by 343.9% during the 4th quarter. EMC Capital Management now owns 13,831 shares of the company's stock valued at $206,000 after acquiring an additional 10,715 shares during the last quarter. Institutional investors own 77.43% of the company's stock.

Organon & Co. Stock Up 2.0%

Shares of OGN traded up $0.19 during mid-day trading on Tuesday, hitting $9.44. 4,168,417 shares of the company's stock were exchanged, compared to its average volume of 4,661,652. The stock's 50-day moving average is $10.81 and its 200-day moving average is $13.75. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. Organon & Co. has a fifty-two week low of $8.01 and a fifty-two week high of $23.10. The company has a market cap of $2.45 billion, a price-to-earnings ratio of 2.83, a P/E/G ratio of 0.90 and a beta of 0.75.

Organon & Co. (NYSE:OGN - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $1.02 earnings per share for the quarter, topping analysts' consensus estimates of $0.89 by $0.13. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The firm had revenue of $1.51 billion during the quarter, compared to analysts' expectations of $1.53 billion. During the same quarter in the prior year, the business earned $1.22 EPS. Organon & Co.'s quarterly revenue was down 6.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 12th. Investors of record on Monday, May 12th will be given a dividend of $0.02 per share. The ex-dividend date is Monday, May 12th. This represents a $0.08 dividend on an annualized basis and a yield of 0.85%. Organon & Co.'s dividend payout ratio (DPR) is 2.78%.

Insider Buying and Selling at Organon & Co.

In related news, VP Daniel Karp acquired 3,500 shares of the stock in a transaction that occurred on Tuesday, May 6th. The stock was purchased at an average cost of $8.24 per share, for a total transaction of $28,840.00. Following the purchase, the vice president now directly owns 46,669 shares in the company, valued at $384,552.56. This represents a 8.11% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Kevin Ali acquired 34,000 shares of the company's stock in a transaction that occurred on Monday, May 5th. The stock was purchased at an average cost of $8.80 per share, for a total transaction of $299,200.00. Following the acquisition, the chief executive officer now owns 282,731 shares in the company, valued at approximately $2,488,032.80. This trade represents a 13.67% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 102,345 shares of company stock valued at $902,430 over the last three months. 1.96% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on OGN shares. Barclays dropped their price target on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. Piper Sandler reduced their price objective on shares of Organon & Co. from $24.00 to $18.00 and set an "overweight" rating for the company in a research note on Thursday, May 15th. Morgan Stanley reduced their price objective on Organon & Co. from $15.00 to $10.00 and set an "equal weight" rating for the company in a report on Monday, May 5th. BNP Paribas upgraded shares of Organon & Co. to a "strong-buy" rating in a research note on Thursday, May 22nd. Finally, Evercore ISI downgraded Organon & Co. from an "outperform" rating to an "inline" rating in a report on Friday, May 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $18.00.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.